2026-07-24 FDA Warning Letter: Thomas Brunner Hygiene GmbH Cited for CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
TL;DR
In short: The FDA Center for Drug Evaluation and Research issued a Warning Letter (Reference 320-26-106) to Thomas Brunner Hygiene GmbH on July 24, 2026, citing significant Current Good Manufacturing Practice (CGMP) violations at its facility in Albershausen, Germany (FEI 3035784232), including failure to conduct adequate testing of finished drug products for active ingredient identity and strength prior to release, and failure to establish adequate written procedures for production control and process validation. The letter also identifies seven syNeo antiperspirant products as unapproved new drugs and misbranded under federal law, prohibiting their introduction into interstate commerce.
Argus analysis
# FDA Warning Letter Analysis: Thomas Brunner Hygiene GmbH
**Company and Violations**
Thomas Brunner Hygiene GmbH, a German manufacturer of over-the-counter antiperspirant products sold under the syNeo brand, received a Warning Letter from FDA's Center for Drug Evaluation and Research on July 24, 2026. The agency identified significant Current Good Manufacturing Practice (CGMP) violations during its review of records submitted in response to an August 2025 inspection request. FDA determined that the syNeo antiperspirant product line—including pump sprays, roll-ons, and wipes—are unapproved new drugs and misbranded under federal law, making them adulterated and prohibited from U.S. interstate commerce.
**Regulatory Citations and Implications**
The violations centered on three core CGMP requirements under 21 CFR parts 210 and 211. First, Thomas Brunner failed to conduct adequate laboratory testing of finished batches before release, particularly assay testing for active ingredient content (21 CFR 211.165(a)). Second, the company lacked written procedures and validation studies for manufacturing, process control, and equipment cleaning (21 CFR 211.100(a) and 211.67(b)). Third, Thomas Brunner did not adequately test incoming raw materials, including identity verification of components like glycerin (21 CFR 211.84(d)). These violations indicate systemic deficiencies in quality assurance and process control rather than isolated deviations.
**Expected Response Timeline and Industry Monitoring**
FDA requested detailed corrective action plans addressing laboratory specifications, testing of distributed reserve samples, process validation documentation, and cleaning validation improvements. Compliance officers in the OTC drug manufacturing sector should monitor whether Thomas Brunner submits adequate responses demonstrating state of control. Industry observers typically expect formal responses within 15 business days, followed by FDA assessment of remediation feasibility. Failure to adequately respond could result in product seizure, import detention, or facility warning regarding future submissions.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Thomas Brunner Hygiene GmbH MARCS-CMS 729018 — July 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-106 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Thomas Brunner Recipient Title Managing Director Thomas Brunner Hygiene GmbH Carl-Benz-Strasse 7 Albershausen 73095 Baden-Württemberg Germany tbrunner3@syneo.de Issuing Office: Center for Drug Evaluation and Research (CDER) United States July 24, 2026 WARNING LETTER Reference number: 320-26-106 Dear Mr. Brunner: This Warning Letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your records. These violations were identified and documented during review of your drug manufacturing facility, Thomas Brunner Hygiene GmbH, located at Carl-Benz-Strasse 7, 73095 Albershausen, Baden-Württemberg, Germany, FDA Establishment Identifier (FEI) 3035784232. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs. Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our August 12, 2025, request and in subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility. This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)). In addition, violations were identified and documented during a review of your product labeling, including your website at the internet address https://syneo.us/ website in April 2026. Based on our review, your “syNeo ANTI-PERSPIRANT PUMP SPRAY,” “syNeo ANTI-PERSPIRANT ROLL-ON,” “syNeo ANTI-PERSPIRANT WET WIPES,”“syNeo MAN ANTI-PERSPIRANT PUMP SPRAY,” “syNeo MAN ANTI-PERSPIRANT ROLL-ON,” “syNeo SOFT ANTI-PERSPIRANT PUMP SPRAY,” and “syNeo SOFT ANTI-PERSPIRANT ROLL-ON” (collectively “syNeo antiperspirant products”) are unapproved new drugs under section 505(a) of the FD&C Act, 21 U.S.C. 355(a). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Thomas Brunner Hygiene GmbH had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Thomas Brunner Hygiene GmbH as of 2026-08-04. Argus ingests new FDA enforcement records daily.
- What FDA violations was Thomas Brunner Hygiene GmbH cited for?
- The FDA Warning Letter to Thomas Brunner Hygiene GmbH (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Thomas Brunner Hygiene GmbH?
- FDA issued the letter (MARCS-CMS 729018) on 2026-07-24 and posted it publicly on fda.gov on 2026-08-04.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-07-24 FDA Warning Letter: Thomas Brunner Hygiene GmbH Cited for CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-thomas-brunner-hygiene-gmbh-2026-07-24-cgmp
"2026-07-24 FDA Warning Letter: Thomas Brunner Hygiene GmbH Cited for CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-thomas-brunner-hygiene-gmbh-2026-07-24-cgmp.
Argus HQ Research. "2026-07-24 FDA Warning Letter: Thomas Brunner Hygiene GmbH Cited for CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated." Digital Empire Holdings LLC. Accessed August 5, 2026. https://argushq.ai/fda/warning-letter/fda-wl-thomas-brunner-hygiene-gmbh-2026-07-24-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_thomas_brunner_hygiene_gmbh_2026_07_24_cgmp_2026,
title = {2026-07-24 FDA Warning Letter: Thomas Brunner Hygiene GmbH Cited for CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-thomas-brunner-hygiene-gmbh-2026-07-24-cgmp},
note = {Accessed: August 5, 2026}
}